-
公开(公告)号:UY33726A
公开(公告)日:2012-06-29
申请号:UY33726
申请日:2011-11-11
Applicant: ABBOTT LAB
Inventor: WOLLER KEVIN R , HELMUT MACK , CURTIN MICHAEL L , SORENSEN BRYAN K , HEYMAN HOWARD R , CLARK RICK F , SHAH OMAR J , MICHAEL MICHAELIDES , CHRIS TSE , ANIL VASUDEVAN , HANSEN TODD M , RAMZI SWEIS , PLIUSHCHEV MARINA A
IPC: A61K31/341 , A61K31/357 , A61K31/381 , A61K31/4015 , A61K31/4025 , A61K31/4035 , A61K31/4155 , A61K31/416 , A61K31/427 , A61K31/4355 , A61K31/438 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , C07D205/12 , C07D209/44 , C07D223/10 , C07D231/02 , C07D231/56 , C07D237/02 , C07D239/02 , C07D241/02 , C07D265/32 , C07D277/02 , C07D295/033 , C07D307/02 , C07D317/10 , C07D319/16 , C07D333/48 , C07D401/14 , C07D403/02 , C07D403/14 , C07D405/02 , C07D471/04 , C07D471/10 , C07D491/048 , C07D491/113
Abstract: Compuestos que inhiben la actividad de la NAMPT, composiciones que contienen los compuestos y métodos para tratar enfermedades en las cuales se expresa la NAMPT. Compuestos que inhiben la actividad de la ROCK, composiciones que contienen los compuestos y métodos para tratar enfermedades en las cuales se expresa la ROCK.
-
公开(公告)号:ZA200705468B
公开(公告)日:2010-03-31
申请号:ZA200705468
申请日:2007-07-04
Applicant: ABBOTT LAB
Inventor: ROHDE JEFFREY J , LINK JAMES T , DINGES JURGEN , YONG HONG , KURUKULASURIYA RAVI , SHUAI QI , PATEL JYOTI R , SORENSEN BRYAN K , YEH VINCE S
IPC: A61K20100101 , A61P20100101 , C07C20100101 , C07D20100101
Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
-
公开(公告)号:BRPI0606228A2
公开(公告)日:2009-06-09
申请号:BRPI0606228
申请日:2006-01-05
Applicant: ABBOTT LAB
Inventor: ROHDE JEFFREY J , LINK JAMES T , PATEL JYOTI R , DINGES JURGEN , SORENSEN BRYAN K , YONG HONG , SHUAI QI
IPC: C07C233/63 , A61K31/165 , A61K31/381 , A61K31/415 , A61K31/42 , A61K31/4409 , A61P3/04 , C07D213/56 , C07D231/12 , C07D261/08 , C07D333/24
Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
-
54.
公开(公告)号:HK1117138A1
公开(公告)日:2009-01-09
申请号:HK08104526
申请日:2008-04-23
Applicant: ABBOTT LAB
Inventor: PATEL JYOTI R , SHUAI QI , LINK JAMES T , ROHDE JEFFREY J , DINGES JURGEN , SORENSEN BRYAN K , WINN MARTIN , YONG HONG , YEH VINCE S
IPC: A61K20060101 , A61P20060101 , C07C20060101 , C07D20060101
Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
-
公开(公告)号:AU2008201198A1
公开(公告)日:2008-04-03
申请号:AU2008201198
申请日:2008-03-12
Applicant: ABBOTT LAB
Inventor: SZCZEPANKIEWICZ BRUCE G , WITTENBERGER STEVEN J , JAE HWAN-SOO , BOYD STEVEN A , KESTER JEFFREY A , KING STEVEN A , WINN MARTIN , HENRY KENNETH J , LIU GANG , TASKER ANDREW S , HUTCHINS CHARLES W , SORENSEN BRYAN K , GELDEM THOMAS W VON
IPC: C07D405/00
-
公开(公告)号:MX2007008239A
公开(公告)日:2007-08-17
申请号:MX2007008239
申请日:2006-01-05
Applicant: ABBOTT LAB
Inventor: YONG HONG , LINK JAMES T , ROHDE JEFFREY J , PATEL JYOTI R , SHUAI QI , DINGES JURGEN , SORENSEN BRYAN K , YEH VINCE S , KURUKULASURIYA RAVI
IPC: C07C233/63 , A61K31/165 , A61K31/381 , A61K31/415 , A61K31/42 , A61K31/4409 , A61P3/04 , A61P3/10 , C07D213/56 , C07D231/12 , C07D261/08 , C07D333/24
Abstract: La presente invencion se refiere a compuestos que son inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa Tipo I. La presente invencion ademas se refiere al uso de inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa Tipo I para el tratamiento de la diabetes tipo 2 no-insulina dependiente, resistencia a la insulina, obesidad, trastornos de lipidos, sindrome metabolico y otras enfermedades y condiciones que son mediadas por la accion excesiva de glucocorticoides.
-
公开(公告)号:DK0885215T3
公开(公告)日:2006-08-14
申请号:DK97905816
申请日:1997-02-12
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , VON GELDERN THOMAS W , SORENSEN BRYAN K , LIU GANG , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , KESTER JEFFREY A , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J JR , WITTENBERGER STEVEN J , KING STEVEN A
IPC: C07D405/04 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/495 , A61K31/506 , A61K31/675 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P25/06 , A61P43/00 , C07D207/16 , C07D211/60 , C07D401/04 , C07D403/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D419/14 , C07D453/02 , C07D471/04 , C07D491/04 , C07F9/572 , C07F9/59
Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
-
58.
公开(公告)号:NZ514170A
公开(公告)日:2005-02-25
申请号:NZ51417097
申请日:1997-02-12
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN SOO , TASKER ANDREW S , VON GELDERN THOMAS V , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A
IPC: A61K31/40 , A61P9/00 , A61P19/00 , C07D207/16 , C07D401/04 , C07D405/04 , C07D405/14 , C07F9/572
Abstract: A process for preparing a compound of formula (I), wherein: E is a carboxy-protecting group and R1 and R2 are loweralkyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl,aminocarbonyalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, heterocyclic and (heterocyclic)alkyl Wherein cycloalkyl, aryl and heterocyclic may be optionally substituted, provided at least one of the following conditions apply: (a) R1 is selected from haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl, and (heterocyclic)alkyl, (b) R2 is selected from haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl, (c) at least on of the optionally substituted aryl groups has at least on substituent selected from hydroxyalkyl and cyano or (d) at least one of the optionally substituted heterocyclic groups has at least one substituent selected from alkyloxycarbonyl, nitro and cyano; comprises a) catalytic hydrogenation of a compound of Formula (II) b)catalytic hydrogenation of the product of step a) in the presence of an acid or a mixture of acids, and c) epimerization of the product of step b) with a base. Also described is the compound (2R, 3R, 4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl-aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid. This compound can be used in the manufacture of a medicament for antagonizing endothelin treating hypertension, congestive heart failure, restinosis cerebral or myocardial ischemia or atherosclerosis, treating coronary angina, cerebral vasospasm, acute and chronic renal failure, gastric ulceration, cyclosporine-induced nephrotoxicity, endotoxin-induced toxicity, asthma, LPL-related lipoprotein disorders, proliferative diseases, acute or chronic pulmonary hypertension, platelet aggregation, thrombosis, IL-2 mediated cardio toxicity nociception, colitis, vascular permeability disorders, ischemia-reperfusion injury raynaud's disease, migraine and for treating bone pain. (62) Divided out of 503365
-
公开(公告)号:TR200101234T2
公开(公告)日:2002-06-21
申请号:TR200101234
申请日:1998-07-27
Applicant: ABBOTT LAB
Inventor: WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , GELDERN THOMAS W VON , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A
IPC: C07D491/048 , A61K31/40 , A61K31/41 , A61K31/423 , A61K31/435 , A61K31/4355 , A61K31/495 , A61K31/506 , A61K31/535 , A61K31/55 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/08 , A61P9/10 , A61P9/12 , A61P9/14 , A61P13/08 , A61P13/12 , A61P21/00 , A61P21/04 , A61P25/06 , A61P35/00 , A61P43/00 , C07D207/16 , C07D207/26 , C07D207/27 , C07D403/04 , C07D405/00 , C07D405/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D491/056 , A61K31/140
-
公开(公告)号:PL348667A1
公开(公告)日:2002-06-03
申请号:PL34866798
申请日:1998-06-08
Applicant: ABBOTT LAB
Inventor: TASKER ANDREW S , WINN MARTIN , BOYD STEVEN A , JAE HWAN-SOO , VON GELDERN THOMAS W , SORENSEN BRYAN K , HENRY KENNETH J
IPC: C07D207/16 , C07D405/04 , A61K31/40
-
-
-
-
-
-
-
-
-